Atossa Genetics, Inc.
Atossa Genetics Inc. is a healthcare company. The Company is engaged in the development of laboratory services, medical devices and therapeutics. Its laboratory services are being developed and performed by its wholly owned subsidiary, the National Reference Laboratory for Breast Health, Inc. (the NRLBH). The NRLBH has developed and is marketing nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Laboratory tests offered or being developed by NRLBH include Pharmacogenomics Test, NAF Cytology Test, NextCYTE Breast Cancer Test and ArgusCYTE Breast Health Test, among others. Its Medical Devices include FullCYTE Breast Aspirator, ForeCYTE Breast Aspirator, FullCYTE Microcatheter and various diagnostic tools, including micro endoscopes. Its Pharmaceuticals include therapeutic to treat ductal hyperplasia, proliferative epithelial disease (PED) or high risk women and therapeutic delivered via its microcatheter to treat ductal carcinoma